IRIS
CAVESTRO, Giulia Martina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.758
EU - Europa 2.658
AS - Asia 1.535
AF - Africa 55
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 8.026
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.675
CN - Cina 1.153
SE - Svezia 635
IE - Irlanda 616
UA - Ucraina 525
FI - Finlandia 394
DE - Germania 267
TR - Turchia 202
SG - Singapore 141
CA - Canada 78
GB - Regno Unito 77
IT - Italia 76
CI - Costa d'Avorio 53
IN - India 18
FR - Francia 16
BE - Belgio 15
IR - Iran 13
RO - Romania 10
NL - Olanda 8
EU - Europa 7
JP - Giappone 5
VE - Venezuela 4
AU - Australia 3
BR - Brasile 3
CZ - Repubblica Ceca 3
ES - Italia 3
GT - Guatemala 3
HU - Ungheria 2
MD - Moldavia 2
RU - Federazione Russa 2
ZA - Sudafrica 2
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
LK - Sri Lanka 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
Totale 8.026
Salva come PNG Salva come JPEG
Città #
Chandler 859
Dublin 615
Jacksonville 538
Dearborn 401
Nanjing 251
Ashburn 212
Beijing 204
Izmir 174
Princeton 154
San Mateo 147
Ann Arbor 122
Shanghai 108
Shenyang 82
Wilmington 81
Toronto 74
Boardman 71
Singapore 69
New York 66
Helsinki 59
Nanchang 59
Abidjan 53
Hebei 53
Kunming 47
Changsha 41
Hefei 38
Jiaxing 38
Jinan 38
Tianjin 36
Norwalk 29
Kocaeli 26
Woodbridge 26
Des Moines 18
Hangzhou 18
Parma 18
Guangzhou 17
Houston 16
Los Angeles 16
Pune 16
Zhengzhou 16
Brussels 15
Grafing 13
Seattle 12
Bremen 11
Ningbo 11
Auburn Hills 9
Cambridge 7
Leawood 7
Rio Saliceto 7
Chengdu 6
Düsseldorf 6
Fremont 6
Haikou 6
Timisoara 6
Taizhou 5
Zanjan 5
Leipzig 4
Maracaibo 4
Milan 4
Taiyuan 4
Washington 4
Wenzhou 4
Baotou 3
Calenzano 3
Changchun 3
Chongqing 3
Espoo 3
Focsani 3
Fuzhou 3
Guatemala City 3
Huzhou 3
Redmond 3
Sacramento 3
Shaoxing 3
Taio 3
Tappahannock 3
Andover 2
Augusta 2
Budapest 2
Chaoyang 2
Chisinau 2
Magdeburg 2
Melbourne 2
Mestre 2
Miami 2
Modena 2
Mountain View 2
Old Bridge 2
Osimo 2
Palermo 2
Portsmouth 2
Quzhou 2
Rome 2
Sabz 2
Sassuolo 2
Alicante 1
Alvaro Obregon 1
Auckland 1
Barcelona 1
Brisbane 1
Brooklyn 1
Totale 5.148
Salva come PNG Salva come JPEG
Nome #
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 84
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 84
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 82
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 78
Association of keratin 8 gene mutation with chronic pancreatitis 75
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 73
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 73
Associations of Spink-1 (N34S) and PRSS-1 (N29I and R122H) gene mutations and chronic pancreatitis in Italy 72
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 70
Bovine lactoferrin as a rescure treatment for Helicobacter pylori infection: results of a multicenter study 68
Study design biases in pancreatic inflammatory diseases. 68
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 68
Lactoferrin in a 1-week triple therapy for eradication of H. pylori 67
A prospective therapeutical one-year study with pantoprazole for patients with oropharingeal picture of GERD 67
PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS 66
Rabepmzole in the treatment of non-responders GERD patients: a prospective six-month study 66
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 65
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 65
Gastroprotective effects of Amtolmetin Guacyl: a new non steroidal antiinflammatory drug that activates inducible gastric niytric oxide synthase 64
Usefullness of gastropanel in different topography of H. pylori related chronic gastritis 64
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 63
Recovery of gastric function after H. pylori eradication in subjects with body atrophic gastritis: a prospective four years study 63
A new marker for monitoring alcohol abuse? A pilot study on heavy drinkers 63
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 63
Topography of gastric damage in H.pylori infection: evaluation by serum pepsinogens levels 62
Are there useful biomarkers for gastric cancer? 62
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 62
OC1.09.3 USEFULNESS OF GASTROPANEL FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASES 62
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 62
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 62
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 62
Esophagitis: acute therapy with omeprazole (Single Dosage Versus BID) 62
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 62
Quality of life in patients with chronic pancreatitis 61
Lactoferrin: mechanism of action, clinical significance and therapeutic 61
Gastropanel as screening of gastric atrophy in primary care 61
PANCREATIC PSEUDOCYSTS FOLLOWING ACUTE PANCREATITIS: RISK FACTORS INFLUENCING THERAPEUTIC OUTCOMES 61
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis 61
Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. 61
Hypercalcemia due to ectopic secretion of parathyriod related protein from pancreatic carcinoma: a case report 60
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 60
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 60
Rabeprazole for the treatment of oropharingeal picture of GERD: a six-month prospective study 59
Therapy of NERD: single Vs double rabeprazole dosage 59
Efficacy of mesalazine in the treatment of symptomatic diverticular disease 59
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 59
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 59
Nonteroidal drug-related gastroduodenal damage in the elderly 58
Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels 57
Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer 57
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 57
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 56
Diagnosis of H. pylori gastritis patterns by means of gastropanel 56
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. 56
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 56
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 56
Clinical usefulness of Gastropanel (SPGI, SPGII, GASTRIN-17, HP SPECIFIC IgG) in the assessment of HP infection 55
Clinical usefulness of serum pepsinogen II in the assessment of H. pylori infection 55
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 55
Gastroesophageal reflux disease in celiac patients: Preliminary results in 35 consecutive patients 55
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 55
Serum pepsinogen II for early assessment of success of H. pylori eradication 55
Use of BOVINE lactoferrin for Helicobacter pylori eradication 54
Lactoferrin in a one week triple therapy for eradication of H. Pylori 54
‘Serological Biopsy’ in first degree relatives of patients with gastric cancer, affected by Helicobacter pylori 54
Macrohematuria caused by a fall in prothrombin activity as a clinical presentation of celiac disease. (I.F. 1.357) 54
Italian consensus guideline for chronic pancreatitis. 54
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 54
THE SIZE OF PANCREATIC PSEUDOCYST DOES NOT INFLUENCE THE OUTCOME OF INVASIVE TREATMENTS 54
Early epigastric pain after PPI administration: exacerbation of Helicobacter pyolori corpus gastritis? 54
Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: prospective 4-year study 53
Relationship between direct and indirect methods for diagnosis of H.pylori infection 53
GENETICS OF CHRONIC PANCREATITIS 53
Hyperbilirubinemia: does it matter? 53
Oral sucrose test and serum pepsinogens for evaluation of H. pylori chronic gastritis 53
Assessment of H. pylori-related chronic gastritis by means of serum pepsinogens and oral sucrose 53
Serum pepsinogen II as a biomarker in management of H. pylori infection 53
Clinical usefulness of gastropanel (sPGI, sPGII, Gastrin, H. pylori specific IgG) in assessment of H. pylori infection in children 52
Symptoms in GERD, NERD and gastroduodenal reflux 52
Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. 52
Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. 52
TAP genes, coding for the transporters associated with antigen processing, contribute to the genetic predisposition to primary sclerosing cholangitis (PSC) 52
The contribution of MHC region genes in the genetic predisposition to primary sclerosing cholangitis (PSC) 52
Serum pepsinogen II and Gastrin-17 (G-17) as markers of NSAIDS gastropathy 51
Chronic atrophic gastritis (GAC) and Helicobacter pylori infection eradication: a 3 years follow-up 51
Lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: results of an open randomized trial 51
Rabeprazole in the treatment of non-responders GERD patients: a prospective six-month study 51
“GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD 51
A new curcumin-based one week therapy for eradication of H. pylori infection 51
Gastro panel® for detection of atrophic gastritis: The “Parma model” 51
Prevalence of CagA status in an high risk area for gastric carcinoma 51
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 51
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 51
“The yellow stomach“: clinical relevance in endoscopical series 50
Disappearance of gallbladder wall lesions after treatment with ursodeozycolic acid 50
HLA-DRB1*04 Allele contribute to the genetic susceptibility of chronic pancreatitis 49
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995) 49
P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS 49
Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care 49
P.1.292: SYMPTOMATOLOGICAL PATTERN IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD), IRRITABLE BOWEL SYNDROME-DIARRHOEA (IBS-D), AND IBS-D PLUS SUDD 49
Totale 5.879
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.852 385 181 113 39 177 288 227 42 136 122 19 123
2020/2021852 17 123 112 2 115 8 108 5 189 32 133 8
2021/2022777 14 15 10 36 43 17 80 108 32 87 92 243
2022/20232.618 294 253 169 234 238 325 7 188 797 9 81 23
2023/2024784 53 84 24 22 56 217 40 61 18 48 77 84
2024/202578 78 0 0 0 0 0 0 0 0 0 0 0
Totale 8.085